Efficacy and Safety of Rituximab Therapy for Lupus Nephritis Among SLE Female Patients; a Retrospective Hospital-Based Study

Figures & data

Table 1 Shows the Age Distributions, Number of Rituximab Doses and the Disease Duration of SLE Patients with Lupus Nephritis on Rituximab Treatment (N = 40)

Duration of Disease (Yrs); M±SD	% of the Patients
Less than 5 years	50
From 5–10 years	40
More than 10 years	10
Age by years	%
Less than 20	10
20–29	37.5
30–39	40
More than 40	12.5
Number of doses	%
Less than 4	15
4	50
More than 4	35

Figure 1 Shows the distribution Q-Q of 6 months outcome by SLEDAI-2K score.

Figure 2 Shows the scores of SLE Disease Activity Index 2000 (SLEDAI 2K) before and after Rituximab treatment (N=40).